Intravenous immunoglobulin as treatment for BK virus: Nephropathy

Pediatric Transplantation

Volumn 13, Issue 1, 2009, Pages 11-13

  Smith, Jodi M ^a   Jordan, Stanley C ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; DACLIZUMAB; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUINOLONE; TACROLIMUS;

AUTOIMMUNE DISEASE; BK VIRUS; DISEASE ASSOCIATION; EDITORIAL; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; VIREMIA; VIRUS INFECTION;

BK VIRUS; CYTOSINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY; KIDNEY TRANSPLANTATION; PHOSPHONIC ACIDS; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 58149312779     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.01105.x     Document Type: Editorial

References (34)

1. Alexander RT, Langlois V, Tellier R, Robinson L, Hebert D. The prevalence of BK viremia and urinary viral shedding in a pediatric renal transplant population: A single-center retrospective analysis. Pediatr Transplant 2006 : 10 : 586 592.
2. Ginevri F, De Santis R, Comoli P, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003 : 75 : 1266 1270.
3. Haysom L, Rosenberg AR, Kainer G, et al. BK viral infection in an Australian pediatric renal transplant population. Pediatr Transplant 2004 : 8 : 480 484.
4. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van Damme-Lombaerts R. Polyomavirus infection in pediatric renal transplant recipients: Evaluation using a quantitative realtime pcr technique. Pediatr Transplant 2004 : 8 : 485 492.
5. Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004 : 4 : 2109 2117.
6. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: Evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006 : 10 : 920 922.
7. Muller A, Beck B, Theilemann K, et al. Detection of polyomavirus BK and JC in children with kidney diseases and renal transplant recipients. Pediatr Infect Dis J 2005 : 24 : 778 781.
8. Smith JM, Dharnidharka V, Talley L, McDonald RA. BK virus nephropathy in pediatric renal transplant recipients: An analysis of the NAPRTCS registry. Clin J Am Soc Nephrol 2007 : 2 : 1037 1042.
9. Andrei G, Snoeck R, Vandeputte M, De Clerc E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997 : 41 : 587 593.
10. Farasati NA, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005 : 79 : 116 118.
11. Keller LS, Peh CA, Nolan J, Bannister KM, Clarkson AR, Faull RJ. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003 : 18 : 1013 1014.
12. Lim WH, Matthew TH, Cooper JE, Bowden S, Russ GR. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology 2003 : 8 : 318 323.
13. Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005 : 5 : 1997 2004.
14. Josephson MA, Gillen D, Javaid B, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003 : 3 : 186 191.
15. Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003 : 75 : 105 112.
16. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005 : 352 : 1157 1158.
17. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 : 345 : 747 755.
18. Jordan SC, Tyan DB. Intravenous gamma globulin (IVIG) inhibits lymphocytotoxic antibody in vitro. J Am Soc Nephrol 1991 : 2 : 803.
19. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994 : 57 : 553 562.
20. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998 : 66 : 800 805.
21. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous gammaglobulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003 : 76 : 631 636.
22. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004 : 15 : 3256 3262.
23. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004 : 17 : 1 8.
24. De Marco T, Damon LE, Colombe B, Keith F, Chatterjee K, Garovoy MR. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997 : 16 : 360 365.
25. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001 : 71 : 53 58.
26. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001 : 72 : 419 422.
27. Azzi A, Fanci R, Ciappi S, Zakrzewska K, Bosi A. Human papillomavirus B19 infection in bone marrow transplantation patients. Am J Hematol 1993 : 44 : 207.
28. Séchet A, Bridoux F, Bauwens M, Ayache RA, Belmouaz S, Touchard G. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc 2002 : 34 : 812.
29. Mofenson LM, Moye J Jr., Bethel J, Hirschhorn R, Jordan C, Nugent R. Prophylactic intravenous immunoglobulin in HIV infected children with CD4+ counts of 0.2 × 10(9)/L or more. Effect on viral, opportunistic and bacterial infections. J Am Med Assoc 1992 : 268 : 483.
30. Barsoum NR, Bunnapradist S, Mougdil A, Toyoda M, Vo A, Jordan SC. Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant 2002 : 2 : 425 428.
31. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006 : 6 : 1906 1912.
32. Puliyanda DRR, Amet N, Hilo L, Jordan SC. IVIG contains antibodies reactive with polyoma BK virus and may represent a therapeutic option for BK nephropathy. Am J Transplant 2003 : 3 : 393.
33. Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant 2009 : 13 : 123 129.
34. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: One-year follow-up of renal allograft recipients. Transplantation 2006 : 81 : 117 120.